Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, source says

Eli Lilly and Novo Nordisk are reportedly nearing agreements with the Trump administration to reduce the prices of their weight-loss drugs, including Lilly's Zepbound, in exchange for Medicare coverage. These deals, which could see lowest doses priced as low as $149 per month, are expected to significantly expand market access and reimbursement for these pharmaceutical companies. This initiative aligns with the administration's broader push to lower drug costs, following similar agreements previously made with Pfizer and AstraZeneca.

Analysis

Eli Lilly (LLY) and Novo Nordisk (NVO) are reportedly nearing agreements with the Trump administration to reduce prices on their weight-loss drugs, including Lilly's Zepbound, in exchange for Medicare coverage. This strategic move, potentially pricing lowest doses at $149/month and Zepbound at $299 ($50 below current direct-to-consumer), is poised to unlock a significant new reimbursement channel. The anticipated Medicare inclusion represents a substantial expansion of market access for these high-demand therapies.

This initiative aligns with the Trump administration's ongoing efforts to lower U.S. prescription drug costs, which are notably higher than in other developed nations. The deals follow similar precedents set by Pfizer (PFE) and AstraZeneca (AZN) regarding Medicaid coverage and most-favored-nation pricing, signaling a consistent regulatory push. The White House's commitment to reducing drug prices underscores a persistent political pressure point for pharmaceutical companies.

The prospect of expanded Medicare coverage, despite price concessions, is viewed positively for LLY and NVO, as indicated by their per-ticker sentiment scores of 0.6. This suggests that the increased volume and broader market penetration from Medicare reimbursement are expected to outweigh the revenue impact of price reductions. The overall market impact is also rated strongly positive (0.7), reflecting potential benefits for the healthcare sector through increased access and predictable reimbursement structures.

Key Decisions for Investors

• Investors should closely monitor the official announcement and finalized terms of the agreements between Eli Lilly and Novo Nordisk and the Trump administration, as specific details on pricing and coverage could influence revenue projections.
• Evaluate the long-term revenue growth potential from significantly expanded Medicare coverage against the immediate impact of reduced per-unit pricing for weight-loss drugs, particularly for LLY and NVO.
• Recognize that these agreements signal a continuing trend of government pressure on drug pricing, which could influence future negotiations and profitability across the pharmaceutical sector.